Metabolic Disorder Therapeutics Market Size, Share & Trends Report

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025

  • Published Date: Jan, 2019
  • Base Year for Estimate: 2017
  • Report ID: GVR-3-68038-011-8
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 145

Industry Insights

The global metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected with obesity and diabetes by 2040.In addition, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth.

As it has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with chronic obesity epidemic with U.S. leading in number of obese cases. In the U.S. alone, an obese person on an average spends around USD 1500 on medical expenses.

U.K. metabolic disorder therapeutics market

Over the years, the global economic condition has improved, especially in developing countries, which have high number of cases of metabolic diseases. Researchers are urging the governments across the globe to take actions and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individual is obese and there have never been reports stating reduction in obesity numbers. These factors are driving the obesity segment growth.

Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a global epidemic with more than 5% of the population affected by the disease requiring a constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes.

Disease Insights

Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effect like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age.

Diabetes was estimated to be the largest segment in 2017 due to wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulator is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits.

Therapy Insights

The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and lack of solid scientific back up. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week.

Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further.

Route of Administration Insights

Based on route of administration, the market is segmented into oral, parenteral and other routes of administration. Oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. Rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by oral route of administration.

Global metabolic disorder therapeutics market

Others segment is also likely to witness a significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need of lifelong diagnosis and multiple dosage therapy. In the recent years, due to the advances in diagnostics, greater emphasis on ground breaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth in near future.

Regional Insights

North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about the metabolic disorders are expected to drive the regional market further.

Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market.

Metabolic Disorder Therapeutics Market Share Insights

Key companies in the global market are Novo Nordisk A/S; Sanofi S.A.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc.; Biocon Ltd.; BioMarin Pharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.

Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data pertaining to the clinical development of Jardiance for reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation

Revenue in USD Billion and CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., Japan, China, Brazil, and South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global metabolic disorder therapeutics market report on the basis of diseases, therapy type, route of administration, and region:

  • Disease Outlook (Revenue, USD Billion, 2014 - 2025)

    • Lysosomal Storage Diseases

      • Gaucher’s Disease

      • Metachromatic Leukodystrophy

      • Hurler - Scheie

      • Sanfilipo A

      • Others

    • Diabetes

    • Obesity

    • Inherited Metabolic Disorders

    • Hypercholesterolemia

  • Therapy Type Outlook (Revenue, USD Billion, 2014 - 2025)

    • Enzyme Replacement Therapy

    • Cellular Transplantation

    • Small Molecule Based Therapy

    • Substrate Reduction Therapy

    • Gene Therapy

    • Drug Therapy

  • Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)

    • Oral

    • Parenteral

    • Others

  • Regional Outlook (Volume, Tons; Revenue, USD Billion, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified